# The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel

Study · id `cardio:ct-nct03599284` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03599284](<https://clinicaltrials.gov/study/NCT03599284>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03599284

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 279 participants.

## Technical summary

Registry record NCT03599284. Randomized; quadruple masking; primary purpose treatment. Start 2018-08-30 (actual); primary completion 2019-06-11 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 279 participants (enrolled count; ClinicalTrials.gov record NCT03599284, source copy `cardio:ctgov-nct03599284-2019-09-23`, retrieved 2026-10-26)
- Started: 2018-08-30 (actual) (ClinicalTrials.gov record NCT03599284, source copy `cardio:ctgov-nct03599284-2019-09-23`, retrieved 2026-10-26)
- Primary completion: 2019-06-11 (actual) (ClinicalTrials.gov record NCT03599284, source copy `cardio:ctgov-nct03599284-2019-09-23`, retrieved 2026-10-26)
- Completion: 2019-07-28 (actual) (ClinicalTrials.gov record NCT03599284, source copy `cardio:ctgov-nct03599284-2019-09-23`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03599284, source copy `cardio:ctgov-nct03599284-2019-09-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03599284-2019-09-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel
- Condition: Coronary Artery Disease
- Condition: Percutaneous Coronary Intervention
- Condition: Platelet Aggregation Inhibitors
- Intervention (Drug): Vicagrel 5mg
- Intervention (Drug): Vicagrel 6mg
- Intervention (Drug): Vicagrel 7.5mg
- Intervention (Drug): Clopidogrel 75mg
- Lead sponsor: Jiangsu vcare pharmaceutical technology co., LTD
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)

## Provenance

Content hash: 3ebd7f49b7cb5a031e4c45d58661f02e55bfe25acd2d23e533db5a33bcfc2717
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
